Dunnigan Syndrome, Lipodystrophy
Conditions
Brief summary
The objective of this work is to identify biomarkers of interest in patients with insulin resistance leading to early disorders of glycemic regulation. For this the investigators want to assay the insulin resistance marker Insulin Regulated Amino Peptidase serique (IRAPs), the plasma lipidome and inflammation markers in 2 populations of insulin-resistant subjects due to Dunnigan's inherited lipodystrophy or overweight/obesity and insulin-sensitive subjects with or without a glycemic regulation disorder objectified during an Oral induced hyperglycemia. The results of the IRAPs, lipidome and inflammation assays will be compared in insulin-resistant subjects, between normoglycemic, prediabetic and diabetic subjects. Correlations will be made between these markers and the deterioration of glycemic regulation as well as with known insulin resistance parameters (HOmeostasis Assessment Model (HOMA), Quantitative Insulin-sensitivity Check Index (QUICKI),Insulin Sensitivity Index (Isi) MATSUDA).
Interventions
OTHERresearch-specific blood sample
blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers
Sponsors
Centre Hospitalier Universitaire de la Réunion
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with Dunnigan's Lipodystrophy OR Non-lipodystrophic insulin-resistant subjects OR Insulin-sensitive non-lipodystrophic subjects * major * Subjects benefiting from metabolic exploration in the Endocrinology, Diabetology and Nutrition department of the Reunion University Hospital. * Subject benefiting from an oral glucose tolerance test (OGTT) during his follow-up in the Endocrinology, Diabetology and Nutrition department of the Reunion University Hospital. * Person affiliated or beneficiary of a social security scheme. * Subject having been informed of the study in progress and having given their written consent.
Exclusion criteria
* Pregnant woman * Person under guardianship or curators or deprived of liberty
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insulin Regulated Amino Peptidase sérique (IRAPs) levels | at inclusion | Insulin Regulated Amino Peptidase sérique (IRAPs) |
| inflammation markers levels | at inclusion | TNF-α (tumor necrosis factors-α), IL-1β (interleukin-1β), IL-2, IL-6, IL-18, IFN-γ (interferon-γ) et MCP-1 (monocyte chemoattractant protein-1), IL-10, IL-4, IL-5 |
| lipidome markers levels | at inclusion | 662 plasma lipid species |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare levels of Insulin Regulated Amino Peptidase sérique (IRAPs) between the 3 categories of participants | at inclusion | Insulin Regulated Amino Peptidase sérique (IRAPs) |
| Compare levels of inflammation markers between the 3 categories of participants | at inclusion | TNF-α (tumor necrosis factors-α), IL-1β (interleukin-1β), IL-2, IL-6, IL-18, IFN-γ (interferon-γ) et MCP-1 (monocyte chemoattractant protein-1), IL-10, IL-4, IL-5 |
| Compare levels of lipidome markers between the 3 categories of participants | at inclusion | 662 plasma lipid species |
Countries
Reunion
Outcome results
None listed